240 related articles for article (PubMed ID: 25048467)
21. miRNA expression profiling of hereditary breast tumors from BRCA1- and BRCA2-germline mutation carriers in Brazil.
Pessôa-Pereira D; Evangelista AF; Causin RL; da Costa Vieira RA; Abrahão-Machado LF; Santana IVV; da Silva VD; de Souza KCB; de Oliveira-Silva RJ; Fernandes GC; Reis RM; Palmero EI; Marques MMC
BMC Cancer; 2020 Feb; 20(1):143. PubMed ID: 32087690
[TBL] [Abstract][Full Text] [Related]
22. Hypermethylation of BRCA1 gene: implication for prognostic biomarker and therapeutic target in sporadic primary triple-negative breast cancer.
Zhu X; Shan L; Wang F; Wang J; Wang F; Shen G; Liu X; Wang B; Yuan Y; Ying J; Yang H
Breast Cancer Res Treat; 2015 Apr; 150(3):479-86. PubMed ID: 25783183
[TBL] [Abstract][Full Text] [Related]
23. High chromosome instability identified by low-pass whole-genome sequencing assay is associated with TP53 copy loss and worse prognosis in BRCA1 germline mutation breast cancer.
Zhu L; Pan JN; Qian Z; Ye WW; Wang XJ; Cao WM
Breast Cancer; 2022 Jan; 29(1):103-113. PubMed ID: 34403063
[TBL] [Abstract][Full Text] [Related]
24. An aCGH classifier derived from BRCA1-mutated breast cancer and benefit of high-dose platinum-based chemotherapy in HER2-negative breast cancer patients.
Vollebergh MA; Lips EH; Nederlof PM; Wessels LFA; Schmidt MK; van Beers EH; Cornelissen S; Holtkamp M; Froklage FE; de Vries EGE; Schrama JG; Wesseling J; van de Vijver MJ; van Tinteren H; de Bruin M; Hauptmann M; Rodenhuis S; Linn SC
Ann Oncol; 2011 Jul; 22(7):1561-1570. PubMed ID: 21135055
[TBL] [Abstract][Full Text] [Related]
25. Genetic and epigenetic characterization of the BRCA1 gene in Brazilian women at-risk for hereditary breast cancer.
Felicio PS; Melendez ME; Arantes LM; Kerr LM; Carraro DM; Grasel RS; Campacci N; Scapulatempo-Neto C; Fernandes GC; de Carvalho AC; Palmero EI
Oncotarget; 2017 Jan; 8(2):2850-2862. PubMed ID: 27926510
[TBL] [Abstract][Full Text] [Related]
26. High-risk human papilloma virus infection, tumor pathophenotypes, and BRCA1/2 and TP53 status in juvenile breast cancer.
Aceto GM; Solano AR; Neuman MI; Veschi S; Morgano A; Malatesta S; Chacon RD; Pupareli C; Lombardi M; Battista P; Marchetti A; Mariani-Costantini R; Podestà EJ
Breast Cancer Res Treat; 2010 Aug; 122(3):671-83. PubMed ID: 19851859
[TBL] [Abstract][Full Text] [Related]
27. High frequency of TP53 mutation in BRCA1 and sporadic basal-like carcinomas but not in BRCA1 luminal breast tumors.
Manié E; Vincent-Salomon A; Lehmann-Che J; Pierron G; Turpin E; Warcoin M; Gruel N; Lebigot I; Sastre-Garau X; Lidereau R; Remenieras A; Feunteun J; Delattre O; de Thé H; Stoppa-Lyonnet D; Stern MH
Cancer Res; 2009 Jan; 69(2):663-71. PubMed ID: 19147582
[TBL] [Abstract][Full Text] [Related]
28. Genetic and clinical landscape of breast cancers with germline BRCA1/2 variants.
Inagaki-Kawata Y; Yoshida K; Kawaguchi-Sakita N; Kawashima M; Nishimura T; Senda N; Shiozawa Y; Takeuchi Y; Inoue Y; Sato-Otsubo A; Fujii Y; Nannya Y; Suzuki E; Takada M; Tanaka H; Shiraishi Y; Chiba K; Kataoka Y; Torii M; Yoshibayashi H; Yamagami K; Okamura R; Moriguchi Y; Kato H; Tsuyuki S; Yamauchi A; Suwa H; Inamoto T; Miyano S; Ogawa S; Toi M
Commun Biol; 2020 Oct; 3(1):578. PubMed ID: 33067557
[TBL] [Abstract][Full Text] [Related]
29. Basal-like breast cancer and the BRCA1 phenotype.
Turner NC; Reis-Filho JS
Oncogene; 2006 Sep; 25(43):5846-53. PubMed ID: 16998499
[TBL] [Abstract][Full Text] [Related]
30. Comparative microRNA profiling of sporadic and BRCA1 associated basal-like breast cancers.
Yan M; Shield-Artin K; Byrne D; Deb S; Waddell N; ; Haviv I; Fox SB
BMC Cancer; 2015 Jul; 15():506. PubMed ID: 26152113
[TBL] [Abstract][Full Text] [Related]
31. Familial breast cancer: clinical response to induction chemotherapy or radiotherapy related to BRCA1/2 mutations status.
Fourquet A; Stoppa-Lyonnet D; Kirova YM; Sigal-Zafrani B; Asselain B; ;
Am J Clin Oncol; 2009 Apr; 32(2):127-31. PubMed ID: 19307946
[TBL] [Abstract][Full Text] [Related]
32. Methylation of Breast Cancer Predisposition Genes in Early-Onset Breast Cancer: Australian Breast Cancer Family Registry.
Scott CM; Joo JE; O'Callaghan N; Buchanan DD; Clendenning M; Giles GG; Hopper JL; Wong EM; Southey MC
PLoS One; 2016; 11(11):e0165436. PubMed ID: 27902704
[TBL] [Abstract][Full Text] [Related]
33. Identification of Novel Breast Cancer Subtype-Specific Biomarkers by Integrating Genomics Analysis of DNA Copy Number Aberrations and miRNA-mRNA Dual Expression Profiling.
Li D; Xia H; Li ZY; Hua L; Li L
Biomed Res Int; 2015; 2015():746970. PubMed ID: 25961039
[TBL] [Abstract][Full Text] [Related]
34. Comprehensive molecular portraits of human breast tumours.
Cancer Genome Atlas Network
Nature; 2012 Oct; 490(7418):61-70. PubMed ID: 23000897
[TBL] [Abstract][Full Text] [Related]
35. Clinical characteristics and outcomes of patients with BRCA1 or RAD51C methylated versus mutated ovarian carcinoma.
Bernards SS; Pennington KP; Harrell MI; Agnew KJ; Garcia RL; Norquist BM; Swisher EM
Gynecol Oncol; 2018 Feb; 148(2):281-285. PubMed ID: 29233532
[TBL] [Abstract][Full Text] [Related]
36. Cyclin E expression in breast cancer: predicting germline BRCA1 mutations, prognosis and response to treatment.
Chappuis PO; Donato E; Goffin JR; Wong N; Bégin LR; Kapusta LR; Brunet JS; Porter P; Foulkes WD
Ann Oncol; 2005 May; 16(5):735-42. PubMed ID: 15802279
[TBL] [Abstract][Full Text] [Related]
37. BRCA1-related gene signature in breast cancer: the role of ER status and molecular type.
Lisowska KM; Dudaladava V; Jarzab M; Huzarski T; Chmielik E; Stobiecka E; Lubinski J; Jarzab B
Front Biosci (Elite Ed); 2011 Jan; 3(1):125-36. PubMed ID: 21196292
[TBL] [Abstract][Full Text] [Related]
38. High prevalence and predominance of BRCA1 germline mutations in Pakistani triple-negative breast cancer patients.
Rashid MU; Muhammad N; Bajwa S; Faisal S; Tahseen M; Bermejo JL; Amin A; Loya A; Hamann U
BMC Cancer; 2016 Aug; 16(1):673. PubMed ID: 27553291
[TBL] [Abstract][Full Text] [Related]
39. Mutation landscape of germline and somatic BRCA1/2 in patients with high-grade serous ovarian cancer.
Eoh KJ; Kim HM; Lee JY; Kim S; Kim SW; Kim YT; Nam EJ
BMC Cancer; 2020 Mar; 20(1):204. PubMed ID: 32164585
[TBL] [Abstract][Full Text] [Related]
40. Classifications within molecular subtypes enables identification of BRCA1/BRCA2 mutation carriers by RNA tumor profiling.
Larsen MJ; Kruse TA; Tan Q; Lænkholm AV; Bak M; Lykkesfeldt AE; Sørensen KP; Hansen TV; Ejlertsen B; Gerdes AM; Thomassen M
PLoS One; 2013; 8(5):e64268. PubMed ID: 23704984
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
